WO2017176001A1 - 제주조릿대 추출물을 포함하는 여성 갱년기 증상 개선용 조성물 - Google Patents
제주조릿대 추출물을 포함하는 여성 갱년기 증상 개선용 조성물 Download PDFInfo
- Publication number
- WO2017176001A1 WO2017176001A1 PCT/KR2017/003269 KR2017003269W WO2017176001A1 WO 2017176001 A1 WO2017176001 A1 WO 2017176001A1 KR 2017003269 W KR2017003269 W KR 2017003269W WO 2017176001 A1 WO2017176001 A1 WO 2017176001A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- composition
- menopausal
- female
- women
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 206010027304 Menopausal symptoms Diseases 0.000 title claims abstract description 43
- 241001299715 Sasa quelpaertensis Species 0.000 title abstract description 4
- 208000017657 Menopausal disease Diseases 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 230000009245 menopause Effects 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 14
- 230000006872 improvement Effects 0.000 claims description 12
- 241000209020 Cornus Species 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 8
- 240000002045 Guettarda speciosa Species 0.000 claims description 8
- 229940072117 fennel extract Drugs 0.000 claims description 8
- 229940069445 licorice extract Drugs 0.000 claims description 8
- 208000020084 Bone disease Diseases 0.000 claims description 7
- 235000020230 cinnamon extract Nutrition 0.000 claims description 7
- 235000020765 fenugreek extract Nutrition 0.000 claims description 7
- 208000019622 heart disease Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 235000021537 Beetroot Nutrition 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 208000021642 Muscular disease Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000005368 osteomalacia Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000007442 rickets Diseases 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 235000013305 food Nutrition 0.000 abstract description 11
- 239000007864 aqueous solution Substances 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 11
- 208000033830 Hot Flashes Diseases 0.000 description 9
- 206010060800 Hot flush Diseases 0.000 description 9
- 230000037406 food intake Effects 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001815 facial effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000008454 Hyperhidrosis Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 208000004483 Dyspareunia Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000004044 Hypesthesia Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 206010029216 Nervousness Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 244000250129 Trigonella foenum graecum Species 0.000 description 3
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 3
- -1 and the like Substances 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000003756 cervix mucus Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 206010013932 dyslexia Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 208000013465 muscle pain Diseases 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 206010046901 vaginal discharge Diseases 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 240000001810 Angelica gigas Species 0.000 description 2
- 235000018865 Angelica gigas Nutrition 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 2
- 210000002229 urogenital system Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000209128 Bambusa Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 1
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 1
- 241000110637 Cuscuta chinensis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- 241000267040 Sasa borealis Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241001092391 Sorbus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000008345 mountainash Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001917 trigonella foenum graecum l. absolute Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Definitions
- the present specification relates to a composition for improving female menopausal symptoms, or preventing or treating female menopausal diseases, including Jeju jejudae extract as an active ingredient.
- Sasa borealis Makino is the smallest of the bamboos and grows in the mountains of south central Korea. Sori is the weakest among bamboo, so only one of the soda is effective in intractable diseases such as diabetes, hypertension, gastritis, gastric ulcer, chronic hepatitis and cancer. In addition, stalks are known to be effective in lowering heat, detoxifying, removing sputum and urinating well, treating inflammation and inhibiting cancer cells. Among them, Sasa Jeju quelpaertensis Nakai ) is an indigenous species that is distributed only in the Hallasan region and grows in a large colony within the distribution area.
- the study on the jeju jeoldae extract has the effect of improving women's menopausal symptoms, prevention and treatment of women's menopausal disease and body heat balance improvement of menopausal women It was found that the present invention has been achieved.
- One aspect of the present invention is to provide a composition for the improvement of female menopausal symptoms, or preventing or treating female menopausal diseases, including the jeju jeoldae extract as an active ingredient.
- One aspect of the present invention to provide a composition for improving the body heat balance of menopausal women including jeju jeoldae extract as an active ingredient.
- One aspect of the present invention provides a composition for improving female menopausal symptoms, or preventing or treating female menopausal diseases, comprising jeju jeoldae extract as an active ingredient.
- the composition is a composition further comprising a soft core extract.
- the composition is a composition further comprising any one or more selected from the group consisting of Tosa extract, fenugreek extract, Angelica extract, cornus extract, cinnamon extract, beetroot extract, small fennel extract and licorice extract .
- the extract is a water extract, C 1 -C 5 alcohol extract or C 1 -C 5 alcohol aqueous solution extract, a composition.
- the jejudae extract is 0.001 to 90% by weight based on the total weight of the composition, the composition.
- the composition for improving the female menopausal symptoms characterized in that to improve the body heat balance of menopausal women.
- the female menopausal symptoms are skin flushing, hot flashes, hot flashes, sweating, numbness, joint pain, muscle pain, reduced skin elasticity, dry skin, fatigue, palpitations, insomnia, depression, anxiety, Composition, which is any one or more of headache, nervousness, vaginal discharge reduction, vaginal dryness, vaginal contractions, dyspareunia and dyslexia.
- the female menopausal disease is a composition, which is a muscular disease, bone disease or heart disease caused by menopause.
- the bone disease is rheumatoid arthritis, degenerative arthritis, osteoporosis, rickets, osteomalacia or paget's diseas of bone due to menopause;
- the heart disease may be angina or arteriosclerosis caused by menopause.
- the composition may be a pharmaceutical composition.
- the composition for improving female climacteric symptoms may be a dietary supplement.
- composition according to one aspect of the present invention has an effect of improving female menopausal symptoms or preventing or treating female menopausal symptoms.
- Composition according to one aspect of the present invention has the effect of improving vaginal dryness of menopausal women.
- composition according to one aspect of the present invention has a rapid temperature change alleviation effect of menopausal women.
- composition according to an aspect of the present invention has a rapid temperature increase relief or rapid temperature decrease alleviation effect of menopausal women.
- Composition according to one aspect of the present invention has a hot flashes or skin flushing effect of menopausal women.
- Composition according to one aspect of the present invention has the effect of improving the discomfort symptoms due to the heat of menopausal women.
- Composition according to one aspect of the present invention has the effect of treating or preventing muscle diseases, bone diseases, heart diseases, skin diseases, neuropsychiatric diseases or sexual function diseases of menopausal women.
- composition according to an aspect of the present invention the skin redness, hot flashes, hot flashes, sweating, numbness, joint pain, muscle pain, reduced skin elasticity, dry skin, fatigue, palpitations, insomnia, depression, anxiety, It has the effect of improving any one or more of headache, nervousness, vaginal discharge, vaginal dryness, vaginal contraction, dyspareunia and dyslexia.
- Composition according to one aspect of the present invention has the effect of improving the body heat balance of menopausal women.
- Figure 3a-b is a photograph of the thermal relaxation effect on the upper body according to the Experimental Example 3 of the present invention.
- Figure 4a-b is a photograph measuring the heat-relaxation effect on the face according to Experimental Example 3 of the present invention.
- Figure 5a-b is a photograph measuring the effect of lowering the body temperature in the hand region according to Experimental Example 3 of the present invention.
- Example 6 is a vaginal symptom evaluation item according to Experimental Example 6 of the present invention.
- One aspect of the present invention provides a composition for improving female menopausal symptoms, or preventing or treating female menopausal diseases, comprising jeju jeoldae extract as an active ingredient.
- An aspect of the present invention provides a method for improving female menopausal symptoms or preventing or treating female menopausal diseases, the method comprising administering to the subject in need thereof an effective amount of the jejusae extract do.
- One aspect of the present invention provides the use of Jeju jerk extract in the manufacture of a composition for ameliorating female menopausal symptoms or preventing or treating female menopausal diseases.
- One aspect of the present invention provides a jeju jang extract for improving female menopausal symptoms, or to prevent or treat female menopausal diseases.
- Jeju jeoridae scientific name is Sasa quelpaertensis It's Nakai .
- Sasa quelpaertensis Nakai is an indigenous species that is distributed only in the Hallasan region and grows in a large colony within the distribution area.
- Jeju bovine barley contains a lot of stored starch in fruit botanicals, and has been used as an important plant for food famine in the Jeju region since ancient times.
- extract includes any material obtained by extracting a component therefrom from a natural product, regardless of the method of extraction or the kind of the component.
- it is a broad concept including the thing which extracted the component melt
- the organic solvent is not particularly limited, C1 ⁇ C5 lower alcohol, glycerol, ethylene, such as methanol, ethanol, isopropyl alcohol, n-propyl alcohol, n-butanol and isobutanol
- Polyhydric alcohols such as glycol, propylene glycol, 1,3-butylene glycol, hydrocarbon solvents such as methyl acetate, ethyl acetate, benzene, n-hexane, diethyl ether, dichloromethane, chloroform, petroleum ether, methyl acetate
- Non-polar organic solvents such as benzene, hexane, chloroform, methylene chloride, dimethyl ether, ethyl acetate and the like.
- the extract may be an extract extracted with water. In another embodiment, the extract may be an extract extracted with C 1 -C 5 alcohol. In another embodiment, the extract may be an extract extracted with ethanol, but is not limited thereto.
- the extract may be included in the composition in the form of a dry powder.
- the extract provides an extract extracted using water, C 1 -C 5 alcohol or C 1 -C 5 alcohol aqueous solution.
- the composition is a composition further comprising a soft core extract.
- Nelumbinis Plumula is the seed of the lotus, the scientific name is called Nelumbinis Plumula .
- the composition further comprises any one or more selected from the group consisting of tosa extract, fenugreek extract, Angelica extract, cornus extract, cinnamon extract, beetroot extract, small fennel extract and licorice extract, female menopause A composition for preventing or treating a symptom.
- Tosa-za is known as the Japanese wild ginseng seed, Cuscuta chinensis Lam. to be.
- Fenugreek is known as the Big Yellow Camellia.
- “Danggui” is known as Korean angelica, Angelica gigas N. to be.
- “Hansuyu” is known as mountain ash, siljou, stone, zucchini, cornus fruit or royal jelly. Cornus officinalis Siebold et Zucc . to be. Cornus in the present invention may use cornus fruit. Cinnamon is also called broiler. Cinnamomum aromaticum Nees to be. Root roots are called Puerariae Radix, Pueraria lobata ( Willd .) Ohwi or Pueraria thunbergii ( Siebold & Zucc.) Benth . Can be used. Foeniculi Fructus Foeniculum vulgare Mill. This can be used. Licorice is Glycyrrhiza glabra Linne This can be used.
- the extract is a water extract, C 1 -C 5 alcohol extract or C 1 -C 5 alcohol aqueous solution extract, a composition.
- the concentration of the C 1 -C 5 alcohol aqueous solution may be 40% to 90% (v / v). In one embodiment, the concentration of the C 1 -C 5 alcohol aqueous solution is at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 66%, at least 67%, 68% Or at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, or at least 80%.
- the concentration of the C 1 -C 5 alcohol aqueous solution is 90% or less, 85% or less, 80% or less, 75% or less, 74% or less, 73% or less, 72% or less, 71% or less, 70% or less, 69 Up to 68%, up to 67%, up to 65%, or up to 60%.
- concentration of the C 1 -C 5 alcohol aqueous solution is within the above range, the effect of improving female menopausal symptoms or treating or preventing female menopausal diseases is excellent.
- the C 1 -C 5 alcohol using any one or two or more selected from the group consisting of methanol, ethanol, isopropyl alcohol, n-propyl alcohol, n-butanol and isobutanol, composition To provide.
- the jejudae extract is 0.001 to 90% by weight based on the total weight of the composition, the composition.
- the Jeju choridae extract may be included 0.1 to 60% by weight based on the total weight of the composition.
- the Jeju stalk extract may be included 0.1 to 30% by weight based on the total weight of the composition.
- the Jeju stalk extract may be included in an amount of 1 to 20% by weight based on the total weight of the composition.
- Jeju sack extract is 0.001% by weight, 0.01% by weight, 0.1% by weight, 1% by weight, 2% by weight, 2.5% by weight, 3% by weight, 5% by weight based on the total weight of the composition Or more, 7 or more, 8 or more, 8.5 or more, 10 or more, 13 or more, 15 or more, 17 or more, 17.5 or more, 20 or more, or 25 It may include more than%.
- the extract of Jeju stalks is 90 wt% or less, 60 wt% or less, 50 wt% or less, 40 wt% or less, 30 wt% or less, 20 wt% or less, 19 wt% or less, 17 wt% based on the total weight of the composition.
- jeju jeoldae extract is within the above range, it is excellent in the improvement of female menopausal symptoms or the treatment or prevention of female menopausal diseases.
- the soft core extract may be included in 0.1 to 15% by weight based on the total weight of the composition.
- the soft core extract is 0.1 wt% or more, 1 wt% or more, 2 wt% or more, 2.5 wt% or more, 3 wt% or more, 5 wt% or more, 7 wt% or more, 8 wt% based on the total weight of the composition. May comprise at least% or at least 8.5% by weight.
- the soft core extract may include 15 wt% or less, 10 wt% or less, 9.5 wt% or less, 8 wt% or less or 5 wt% or less based on the total weight of the composition.
- the earth and sand extract, fenugreek extract, Angelica extract or cornus extract may be included in 0.1 to 5% by weight based on the total weight of the composition.
- the cinnamon extract or the root extract may be included in 0.1 to 3% by weight based on the total weight of the composition.
- the small fennel extract or licorice extract may be included in 0.1 to 2% by weight based on the total weight of the composition.
- One aspect of the present invention provides a composition comprising 50 to 150 parts by weight of the jeju jeoldae extract and 50 to 150 parts by weight of the soft core extract as an active ingredient.
- the composition for improving the female menopausal symptoms may be a composition, characterized in that to improve the body heat balance of menopausal women.
- the female menopausal symptoms are skin flushing, hot flashes, hot flashes, sweating, numbness, joint pain, muscle pain, reduced skin elasticity, dry skin, fatigue, palpitations, insomnia, depression, anxiety, Headache, nervousness, vaginal discharge reduction, vaginal dryness, vaginal contraction, dyspareunia and dyslexia.
- the female climacteric disease may be a muscular disease, bone disease or heart disease caused by menopause.
- the bone disease is rheumatoid arthritis, degenerative arthritis, osteoporosis, rickets, osteomalacia or paget's diseas of bone due to menopause;
- the heart disease may be angina or arteriosclerosis caused by menopause.
- the composition may be a pharmaceutical composition.
- the composition provides a composition formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions.
- the pharmaceutical composition may further comprise, in one aspect, suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
- suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
- the carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- the pharmaceutical composition may be formulated in the form of powder, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterile injectable solutions according to conventional methods. .
- Solid preparations for oral administration may include tablets, pills, powders, granules, capsules and the like. Such solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, in addition to the active ingredient. In addition to simple excipients, lubricants such as magnesium styrate talc may also be included.
- Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to commonly used simple diluents such as water and liquid paraffin.
- Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
- the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
- As the base of the suppository witepsol, macrogol, tween 61, laurin, cacao butter, glycerogelatin and the like can be used.
- the dosage of the extracts disclosed herein may vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration, and the duration and may be selected from the ranges commonly used in the art.
- the daily dose of the active ingredient may be 0.0001 to 0.5 g / kg on a dry weight basis, and in one aspect, 0.001 to 0.1 g / kg.
- the composition may be a food composition.
- the composition for improving the female menopausal symptoms may be a health functional food composition.
- a health functional food composition for example, there are various foods, beverages, gums, teas, vitamin complexes, dietary supplements, and the like, and may be used in the form of powders, granules, tablets, capsules, or beverages.
- the food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials.
- the amount of the active ingredient included in the food or beverage may include 0.001 to 90% by weight of the total food weight in the case of a general food composition, but is not limited thereto.
- the health food composition may include 10 to 90% by weight of the total food weight, but is not limited thereto.
- the daily dose of the active ingredient when ingested as a food composition may be 0.0001 ⁇ 0.1g / kg on a dry weight basis, but is not limited thereto.
- the composition may contain other ingredients and the like that can give a synergistic effect to the main effect within a range that does not impair the main effect of the present invention.
- it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
- additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
- supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included.
- the components may be appropriately selected and blended by those skilled in the art according to the formulation or purpose of use, and the amount of the additives may be selected within a range that does not impair the object and effect of the present invention.
- the amount of the components added may range from 0.01-5% by weight, more specifically 0.01-3% by weight, based on the total weight of the composition.
- Formulations of the compositions according to the invention can take the form of solutions, emulsions, viscous mixtures, tablets, powders, tablets, carces, liquids, granules, pills, flakys, pastes, syrups, gels, jellies, bars or edible flakes. It may be administered in a variety of ways, such as simple drinking, injection, spray or squeeze.
- Jeju chopsticks purchased from Samyoung Food Industry Co., Ltd.
- the leaves of the Jeju chopsticks were separated.
- the weight ratio of the washed jeju jeoldae leaves and purified water is added to the extractor in the ratio of 1: 8, and then extracted by extracting at 95 °C ⁇ 2 °C for 4 hours.
- the extract is cooled to 75 ° C. ⁇ 2 ° C. and filtered using a microfilter (5 ⁇ m).
- the filtered extract is concentrated under reduced pressure to 35 ⁇ 40 Brix.
- the concentrated solution is dried on a spray dryer to prepare Jeju sack extract in powder form.
- the prepared extracts were prepared in Examples 1 to 3 using the same ingredients as in Table 1 below.
- Excipients in Table 1 included tapioca starch, glycerin, honey, crystalline cellulose and sweeteners.
- Example 1 Example 2 Example 3 Jeju sack extract 700 mg 350 mg 105mg Soft core extract - 350 mg 105mg Tosa Extract - - 84mg Fenugreek extract - - 84mg Angelica Extract - - 84mg Cornus Extract - - 84mg Cinnamon Extract - - 56mg Beetroot Extract - - 56mg Small Fennel Extract - - 28mg Licorice extract - - 14mg Excipient 3050 mg 3050 mg 3050 mg Total (mg) 3750 mg 3750 mg 3750 mg
- composition of Examples 1 to 3 prepared in the form of 3.75g pill to test subjects of the following experimental example, to take 1 pill, 4 weeks per day, the results were measured before and after ingestion.
- the Kupperman Index and the Menopause Rating Scale are one of the leading indicators used in the menopausal syndrome questionnaire. Recently, clinical trials using MRS have been on the rise. The index is being used more. In other words, both the Cooperman index and the MRS are used as clinical indicators for KFDA menopausal women's health functional authorization. Thus, the Cooperman index or MRS assessment of the experimenter may prove that the substance is effective in improving female menopausal symptoms or preventing or treating female menopausal diseases.
- Menopausal women were selected according to the following criteria.
- menopausal symptoms the degree of menopausal symptoms is recorded and scored. It consists of 12 questions and uses a 4-point scale (0-None, 1-Slightly, 2-Medium, 3-Severe), and the higher the score, the more severe the menopausal symptoms.
- the Cooperman index metric is shown in FIG. 1.
- Examples 1 to 3 of the menopausal women were evaluated before and after KI score change and item score change.
- Example 3 containing the Jeju chopsticks extract and the Jeju chopsticks components as shown in Table 2 below.
- ingestion of Examples 1 to 3 was lower than the Cooperman index score compared to before ingestion, and especially in Example 3, the effect was the best.
- MRS Menopause Rating Scale
- Examples 1 to 3 were evaluated for the change of MRS score and item-specific score before and after ingestion in the menopausal women.
- Week 4 16.98 ⁇ 3.03 14.98 ⁇ 3.05 10.32 ⁇ 2.12
- Example 3 the menopausal symptoms improvement effect appeared in the composite (Examples 1 to 3) comprising the jeju jeoldae extract and jeju jeoldae components as shown in Table 3.
- the intake of Examples 1 to 3 was lower than that before intake, the MRS score was measured, especially in Example 3, the effect was the best.
- menopausal women the body undergoes rapid temperature changes frequently during daily life, resulting in hot flashes and sleep disturbances.
- the menopausal female test subjects 60 Continuous temperature changes were measured.
- thermoregulation was evaluated by the change of average body temperature and standard deviation. Analyze body temperature data to determine body temperature mean and standard deviation for each subject.
- Example 1 Example 2
- Example 3 Week 0 2.12 ⁇ 0.08 2.08 ⁇ 0.12 2.29 ⁇ 0.21
- Week 4 1.84 ⁇ 0.31 1.01 ⁇ 0.61 0.81 ⁇ 0.55
- the upper body, face, and hands are photographed and analyzed using the thermal imaging camera R300S (NEC, Japan). The skin temperature of each site was evaluated. Infrared cameras always maintain a constant angle and distance when photographing test sites.
- FIGS. 3A-3B and 4A-4B illustrate a test subject who consumed Example 1
- FIGS. 3B and 4B illustrate a test subject who consumed Example 3.
- the original was a color drawing, and grayscale was applied in the process of converting the color drawing into a black and white drawing.
- the color display by temperature located at the bottom of FIG. 3 the color scale for each skin temperature is displayed, and the skin temperature is higher when positioned to the right (red series in the original), and the skin temperature is lower when used to the left (blue series in the original). Is displayed.
- the color scale for each skin temperature is displayed, and the skin temperature is higher as it goes to the top (red in the original) and the skin temperature as it goes down in the lower (blue in the original). Is displayed.
- FIG. 5A is a test subject ingesting Example 1
- FIG. 5B is a test subject ingesting Example 3.
- the original was a color drawing, and grayscale was applied in the process of converting the color drawing into a black and white drawing.
- the color display by temperature located on the right side of FIG. 5 the color scale for each skin temperature is displayed. The skin temperature is higher as it goes to the top (the red system in the original) and the skin temperature is lower as it goes to the bottom (the blue system in the original). Is displayed.
- Example 1 and Example 3 As described above, when menopausal women ingest Example 1 and Example 3 according to an aspect of the present invention, the temperature of the upper body with a high temperature is lowered and the temperature of the cold area is increased, thereby improving heat balance throughout the body. The effect could be confirmed.
- the skin color change of the facial areas of 60 menopausal female test subjects who consumed the compositions of Examples 1 to 3 were measured. Measurements are taken without hot flashes or sweating.
- Skin moisturization of the cheek area is measured using a Corneometer CM825 (Courage and Khazaka, Germany). It is a principle to measure the capacitance of the electric current conducted through the electrode gap adhering to the skin surface. The average value of three times of moisturization is measured and evaluated. The higher the moisture content of the skin, the higher the figure.
- Example 1 Example 2
- Example 3 Week 0 63.90 ⁇ 12.99 61.34 ⁇ 15.10 61.87 ⁇ 15.38 Week 4 68.30 ⁇ 13.17 69.92 ⁇ 14.70 73.16 ⁇ 13.28
- a questionnaire was presented for changes in the genitourinary system of menopausal women and scored by recording the degree of symptoms.
- the 60 menopausal female test subjects who consumed the compositions of Examples 1 to 3 were surveyed for symptoms appearing according to changes in the genitourinary system of menopausal women.
- the questionnaire consisted of a total of five questions, using a 4-point scale (0-None, 1-Slightly, 2-Normal, 3-Severe), and the higher the score, the more severe the discomfort symptoms of the female organ were judged. Evaluation items of are shown in FIG.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
실시예 1 | 실시예 2 | 실시예 3 | |
제주조릿대 추출물 | 700mg | 350mg | 105mg |
연자심 추출물 | - | 350mg | 105mg |
토사자 추출물 | - | - | 84mg |
호로파 추출물 | - | - | 84mg |
당귀 추출물 | - | - | 84mg |
산수유 추출물 | - | - | 84mg |
계피 추출물 | - | - | 56mg |
칡뿌리 추출물 | - | - | 56mg |
소회향 추출물 | - | - | 28mg |
감초 추출물 | - | - | 14mg |
부형제 | 3050mg | 3050mg | 3050mg |
Total (mg) | 3750mg | 3750mg | 3750mg |
KI score | 실시예1(n=20) | 실시예2(n=20) | 실시예3(n=20) |
Week 0 | 18.12±0.26 | 18.31±0.56 | 18.27±0.20 |
Week 4 | 14.31±0.45 | 11.91±0.14 | 9.03±0.97 |
MRS score | 실시예1(n=20) | 실시예2(n=20) | 실시예3(n=20) |
Week 0 | 24.91±3.24 | 25.25±2.16 | 25.80±2.83 |
Week 4 | 16.98±3.03 | 14.98±3.05 | 10.32±2.12 |
체온편차(℃) | 실시예1 | 실시예2 | 실시예3 |
Week 0 | 2.12±0.08 | 2.08±0.12 | 2.29±0.21 |
Week 4 | 1.84±0.31 | 1.01±0.61 | 0.81±0.55 |
피부붉은기(S) | 실시예1 | 실시예2 | 실시예3 |
Week 0 | 45.23±13.09 | 46.04±21.25 | 45.88±18.31 |
Week 4 | 38.11±9.97 | 37.07±10.20 | 30.09±8.79 |
피부보습(A.U.) | 실시예1 | 실시예2 | 실시예3 |
Week 0 | 63.90±12.99 | 61.34±15.10 | 61.87±15.38 |
Week 4 | 68.30±13.17 | 69.92±14.70 | 73.16±13.28 |
질 증상 | 실시예1(n=20) | 실시예2(n=20) | 실시예3(n=20) |
Week 0 | 6.51±3.90 | 6.73±3.11 | 6.03±2.97 |
Week 4 | 4.08±3.01 | 3.81±2.66 | 2.64±2.03 |
Claims (11)
- 제주조릿대 추출물을 유효성분으로 포함하는, 여성 갱년기 증상의 개선용, 또는 여성 갱년기 질환의 예방 또는 치료용 조성물.
- 제 1항에 있어서,상기 조성물은 연자심 추출물을 더 포함하는, 조성물.
- 제 2항에 있어서,상기 조성물은 토사자 추출물, 호로파 추출물, 당귀 추출물, 산수유 추출물, 계피 추출물, 칡뿌리 추출물, 소회향 추출물 및 감초 추출물로 이루어진 군에서 선택된 어느 하나 이상을 더 포함하는, 조성물.
- 제 1항에 있어서,상기 추출물은 물 추출물, C1-C5 알코올 추출물 또는 C1-C5 알코올 수용액 추출물인, 조성물.
- 제 1항에 있어서,상기 제주조릿대 추출물은 조성물 전체 중량을 기준으로 0.001 내지 90 중량%인, 조성물.
- 제1항에 있어서,상기 여성 갱년기 증상의 개선용 조성물은 갱년기 여성의 신체 열 균형을 개선하는 것을 특징으로 하는, 조성물.
- 제1항에 있어서,상기 여성 갱년기 증상의 개선용 조성물은 갱년기 여성의 신체 열 균형을 개선하는 것을 특징으로 하는, 조성물.
- 제1항에 있어서,상기 여성 갱년기 질환은 갱년기에 의한 근육질환, 골 질환 또는 심장 질환인, 조성물.
- 제8항에 있어서,상기 골 질환은 갱년기에 의한 류마티스성 관절염, 퇴행성 관절염, 골다공증, 구루병, 골 연화질환 또는 파제트 골 질환(Paget's diseas e of bone)이거나; 또는상기 심장 질환은 갱년기에 의한 협심증 또는 동맥경화증인, 조성물.
- 제 1항 내지 제 9항 중 어느 한 항에 있어서,상기 조성물은 약학 조성물인, 조성물.
- 제 1항 내지 제 7항 중 어느 한 항에 있어서,상기 여성 갱년기 증상의 개선용 조성물은 건강기능 식품 조성물인, 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780022479.0A CN108883146B (zh) | 2016-04-05 | 2017-03-27 | 包含奎尔帕特赤竹提取物的用于改善妇女更年期症状的组合物 |
JP2018544206A JP7034927B2 (ja) | 2016-04-05 | 2017-03-27 | 耽羅笹抽出物を含む女性更年期症状の改善用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160041622A KR101845245B1 (ko) | 2016-04-05 | 2016-04-05 | 제주조릿대 추출물을 포함하는 여성 갱년기 증상 개선용 조성물 |
KR10-2016-0041622 | 2016-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017176001A1 true WO2017176001A1 (ko) | 2017-10-12 |
Family
ID=60000497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/003269 WO2017176001A1 (ko) | 2016-04-05 | 2017-03-27 | 제주조릿대 추출물을 포함하는 여성 갱년기 증상 개선용 조성물 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP7034927B2 (ko) |
KR (1) | KR101845245B1 (ko) |
CN (1) | CN108883146B (ko) |
TW (1) | TWI717487B (ko) |
WO (1) | WO2017176001A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102317303B1 (ko) * | 2019-05-14 | 2021-10-26 | 한국식품연구원 | 락토바실러스 아시도필루스를 포함하는 갱년기 여성의 안면홍조, 손발저림, 또는 가슴 두근거림의 예방, 개선, 또는 치료용 조성물 |
KR102317304B1 (ko) * | 2019-05-14 | 2021-10-26 | 한국식품연구원 | 락토바실러스 아시도필루스를 포함하는 갱년기 여성의 신경과민, 개미환각, 불면증, 현기증, 또는 피로의 예방, 개선, 또는 치료용 조성물 |
KR20220144090A (ko) | 2021-04-19 | 2022-10-26 | 주식회사 골드레벤 | 트랜스여성을 위한 필요성분을 제공하는 신규한 복합 추출물 및 그 제조방법, 이를 유효성분으로 함유하는 화장료 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150102515A (ko) * | 2014-02-28 | 2015-09-07 | 이화여자대학교 산학협력단 | 제주 조릿대 추출물을 유효성분으로 포함하는 염증성 장질환 예방, 치료, 또는 개선용 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1250748B (it) * | 1991-08-02 | 1995-04-21 | Poli Ind Chimica Spa | Formulazioni utili per il trattamento della secchezza vaginale |
KR20130064178A (ko) * | 2011-12-08 | 2013-06-18 | (주)아모레퍼시픽 | 제주조릿대 추출물을 함유하는 피부 외용제 조성물 |
CN102526385B (zh) * | 2012-01-17 | 2013-07-24 | 丁敏 | 一种治疗更年期综合征的药剂 |
-
2016
- 2016-04-05 KR KR1020160041622A patent/KR101845245B1/ko active IP Right Grant
-
2017
- 2017-03-27 JP JP2018544206A patent/JP7034927B2/ja active Active
- 2017-03-27 CN CN201780022479.0A patent/CN108883146B/zh active Active
- 2017-03-27 WO PCT/KR2017/003269 patent/WO2017176001A1/ko active Application Filing
- 2017-03-28 TW TW106110286A patent/TWI717487B/zh active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150102515A (ko) * | 2014-02-28 | 2015-09-07 | 이화여자대학교 산학협력단 | 제주 조릿대 추출물을 유효성분으로 포함하는 염증성 장질환 예방, 치료, 또는 개선용 조성물 |
Non-Patent Citations (4)
Title |
---|
GRADY, D.: "MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial", MENOPAUSE, vol. 16, no. 3, 2009, pages 458 - 465 * |
KIM ET AL: "Effects of Herbal Mixture Extracts Containing Angelica gigas Nakai and Cuscuta chinensis Lam. on Menopausal Symptoms in Ovariectomized Rats", JOURNAL OF THE KOREAN SOCIETY OF FOOD SCIENCE AND NUTICION, vol. 45, no. 8, August 2016 (2016-08-01), pages 1083 - 1089, XP055602236 * |
LEE, B.: "Kaempferol isolated from Nelumbo nucifera inhibits lipid accumulation and increases fatty acid oxidation signaling in adipocytes", JOURNAL OF MEDICINAL FOOD, vol. 18, no. 123, 2015, pages 1363 - 1370 * |
RYOU, S. H.: "Effects of green tea or Sasa quelpaertensis bamboo leaves on plasma and liver lipids, erythrocyte Na efflux, and platelet aggregation in ovariectomized rats", NUTRITION RESEARCH AND PRACTICE, vol. 6, no. 2, 2012, pages 106 - 112, XP055602230 * |
Also Published As
Publication number | Publication date |
---|---|
CN108883146A (zh) | 2018-11-23 |
CN108883146B (zh) | 2023-12-12 |
JP7034927B2 (ja) | 2022-03-14 |
KR101845245B1 (ko) | 2018-04-04 |
KR20170114534A (ko) | 2017-10-16 |
JP2019513693A (ja) | 2019-05-30 |
TWI717487B (zh) | 2021-02-01 |
TW201735939A (zh) | 2017-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010058926A2 (ko) | 생강 추출물 또는 쇼가올을 포함하는 약학 조성물 | |
KR101887157B1 (ko) | 제주조릿대 추출물을 포함하는 여성 갱년기 증상 개선용 조성물 | |
WO2010104309A9 (ko) | 위장질환의 예방 또는 개선용 조성물 | |
WO2017176001A1 (ko) | 제주조릿대 추출물을 포함하는 여성 갱년기 증상 개선용 조성물 | |
WO2018174448A1 (ko) | 백출, 상심자, 구기자, 용안육, 우슬, 두충 및 천문동의 조합생약 추출물을 유효성분으로 함유하는 갱년기증후군의 치료 및 예방을 위한 조성물 및 이의 용도 | |
WO2015002391A1 (ko) | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 | |
WO2018026103A1 (ko) | 인삼 꽃대 추출물을 포함하는 세포 재생용 조성물 | |
WO2018190501A1 (ko) | 인삼 꽃대 추출물을 포함하는 항염증용 조성물 | |
WO2022045418A1 (ko) | 구절초 추출물을 포함하는 통증 완화용 또는 항산화용 건강기능식품 | |
WO2011139118A2 (en) | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease | |
WO2019124854A1 (ko) | 혼합 추출물 또는 이의 분획물을 포함하는 안구건조증 예방 또는 치료용 조성물 | |
WO2010008150A2 (ko) | 삼백초와 황금의 혼합 추출물을 유효성분으로 함유하는 골다공증 예방 또는 치료용 조성물 | |
WO2018131780A1 (ko) | 위염 또는 소화성궤양 예방 또는 치료용 조성물 | |
WO2014133286A1 (ko) | 한인진 및 울금의 추출물을 유효성분으로 포함하는 비만 관련 질환의 예방, 억제 또는 치료용 조성물 | |
WO2017082501A1 (ko) | 번행초 추출물을 포함하는 갱년기 장애의 예방 또는 치료용 조성물 | |
WO2017135637A1 (ko) | 인삼 꽃대 추출물을 포함하는 육모 촉진 또는 탈모 방지용 조성물 | |
WO2017069506A1 (ko) | 울금 및 감초 추출물의 혼합물을 유효성분으로 함유하는 갱년기 증상 예방 및 치료용 약학적 조성물 | |
WO2012105816A2 (ko) | 새콩 분말 또는 이의 추출물을 포함하는 당뇨병 및 당뇨합병증 예방 및 치료를 위한 조성물 | |
WO2019212202A1 (ko) | 강황추출물 및 쌀눈대두 발효추출물을 포함하는 간보호용 조성물 | |
WO2016175559A2 (ko) | 지모와 두릅의 복합 추출물을 함유하는 탈모 방지 및 발모 개선용 조성물 | |
WO2016003120A1 (ko) | 알피나 골무꽃 추출물을 포함하는 미백용 조성물 | |
WO2021070999A1 (ko) | 비만, 당뇨, 고지혈증 및 지방간을 포함하는 대사증후군의 예방, 개선 또는 치료용 조성물 | |
WO2014133276A1 (ko) | 북두근, 북두근 추출물, 북두근 오니 또는 북두근 맥아 효소액 추출물을 유효성분으로 함유하는 식욕부진 예방 또는 치료용 조성물 | |
WO2023022244A1 (ko) | 간 보호용 또는 간 질환 예방 또는 개선용 조성물 | |
WO2019004626A1 (ko) | 생약재 추출물을 유효성분으로 포함하는 폐경기 증후군의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018544206 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201780022479.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17779301 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17779301 Country of ref document: EP Kind code of ref document: A1 |